About Ethypharm
Ethypharm is a company based in Saint-cloud (France) founded in 1977 was acquired by PAI Partners in May 2016. Ethypharm has raised $248.09 million across 5 funding rounds from investors including Goldman Sachs, J P Morgan and Biovail. Ethypharm has completed 2 acquisitions, including DB Ashbourne and Martindale Pharma. Ethypharm offers products and services including CNS Medicines and Hospital Injectables. Ethypharm operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Saint-cloud, France
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ethypharm Group
-
Annual Revenue
$167.87 M (USD)-4as on Dec 31, 2016
-
Net Profit
$23.52 M (USD)85as on Dec 31, 2016
-
EBITDA
Not available
-
Total Equity Funding
$248.09 M (USD)
in 5 rounds
-
Latest Funding Round
$557.3 K (USD), Grant
Dec 21, 2023
-
Investors
Goldman Sachs
& 5 more
-
Employee Count
Not available
-
Investments & Acquisitions
DB Ashbourne
& 1 more
-
Acquired by
PAI Partners
(May 07, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ethypharm
Ethypharm offers a comprehensive portfolio of products and services, including CNS Medicines and Hospital Injectables.
Treatments for severe pain and addiction disorders
Medications for critical care situations
People of Ethypharm
Unlock access to complete
Software Development Team
23 people
Product Management Team
10 people
Leadership Team
9 people
Sales and Marketing
7 people
Responsable Team
7 people
Human Resources and Administration
7 people
Head Team
6 people
Senior Team
6 people
Unlock access to complete
Funding Insights of Ethypharm
Ethypharm has successfully raised a total of $248.09M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $557.3 thousand completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ethypharm
Ethypharm has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, J P Morgan and Biovail.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment banking services are delivered across multiple financial sectors.
|
Locked | Locked | Locked | |
|
Astorg is engaged in private equity investment management.
|
Locked | Locked | Locked | |
|
Private equity investments in market-leading companies across global sectors.
|
Locked | Locked | Locked |
Investor details for Ethypharm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ethypharm
Ethypharm has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include DB Ashbourne and Martindale Pharma.
Investment portfolio details for Ethypharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Procurement platform for generic medicines is provided by DB Ashbourne.
|
Locked | Locked | 2010 | Locked | |
|
Membrane-based humidifiers for fuel cell systems are manufactured.
|
Locked | Locked | 1787 | Locked |
Complete acquisition details for Ethypharm
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Ethypharm
Detailed financials for Ethypharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ethypharm Comparisons
Peer comparison for Ethypharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ethypharm
Ethypharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Ethypharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ethypharm
Complete news archive for Ethypharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ethypharm
Ethypharm was founded in 1977 and raised its 1st funding round 25 years after it was founded.
Ethypharm is headquartered in Saint-cloud, France.
Bertrand Deluard is the current CEO of Ethypharm.
Ethypharm is a funded company, having raised a total of $248.09M across 5 funding rounds to date.
Annual revenue of Ethypharm is $167.87M as on Dec 31, 2016.
Ethypharm was founded in 1977 in Saint-Cloud, France, within the pharmaceutical sector. Drugs and drug delivery systems are developed to address pain and addiction. A portfolio including morphine, fentanyl, tramadol, oxycodone, etodolac, triamcinolone hexacetonide, and episil is maintained for pain management. Additional efforts target alcohol dependence, overdose prevention, and opioid replacement therapies, with operations centered in Europe.
Ethypharm's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Ethypharm offers CNS Medicines and Hospital Injectables.
Ethypharm has made 2 acquisitions, including DB Ashbourne, and Martindale Pharma.
Ethypharm has 6 investors. Key investors include Goldman Sachs, J P Morgan, Biovail, Ministry of Economy, Finance and Industrial and Digital Sovereignty, and Astorg.